Abstract
Background
Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks of disease complications due to dampened immune response. However, it has been speculated that overactive immune response could drive clinical deterioration and, based on this hypothesis, several immunosuppressants are currently being tested as potential treatment for COVID-19.
Methods
In this paper we report on a patient that has been treated with ocrelizumab (a B-cell depleting monoclonal antibody) for primary progressive multiple sclerosis who developed COVID-19.
Results
Despite complete B cell depletion, patient symptoms abated few days after hospitalization, and he was discharged to home-quarantine. Phone interview follow-up confirmed that, after 14 days, no new symptoms occurred.
Discussion
This report supports the putative role of immunosuppressive therapy in COVID-19 affected patients.
【초록키워드】 COVID-19, immune response, therapy, Hospitalization, multiple sclerosis, monoclonal antibody, Symptom, B cell, Patient, death, Complication, Follow-up, coronavirus disease 19, disease, Immunosuppressant, B-cell, Hypothesis, Potential treatment, immunosuppressive, Elderly patient, Clinical deterioration, high risk, Support, higher risk, Complete, disease entity, overactive, Result, tested, occurred, treated, infected patient, discharged, depleting, COVID-19 affected patients, patient symptom, patients with comorbidity, 【제목키워드】 COVID-19, Immunosuppression, Patient, Protective, treated,